Jones Day is representing Infinity Pharmaceuticals.
Jones Day represents Infinity Pharmaceuticals, Inc. in the establishment of a global patent portfolio related to IPI-549.
IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
The Jones Day team is led by Michael Bruner (Picture).
Involved fees earner: Michael Bruner – Jones Day;
Law Firms: Jones Day;
Clients: Infinity Pharmaceuticals Inc;